Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Clopidogrel non-responder is a common dilemma in the management of post-percutaneous coronary intervention (PCI) management. Clopidogrel is metabolized by CYP2C19. The genetic variations in CYP2C19 can affect the efficacy and bioavailability of the drug that can be checked via genotype testing of the gene. This study evaluates the impact of genotype versus conventional guided P2Y12 inhibitor therapy on post-PCI patient outcomes.
Methods: Guided by PRISMA and AMSTAR-2, we analyzed 10 trials comparing genotype-guided and conventional P2Y12 inhibitor therapy in post-PCI patients. Our search, spanning up to October 2022 across major databases, focused on adult populations undergoing PCI, assessing outcomes like mortality, MACE, myocardial infarction, stroke, stent thrombosis, and bleeding events.
Results: A total of 10 studies involving 4300 patients were selected in pooled analysis, genotype-guided therapy markedly reduced all-cause mortality (RR: 0.59; 95% CI: 0.37-0.95) and MACE (RR: 0.66; 95% CI: 0.49-0.88), without a significant increase in bleeding events (RR: 0.83; 95% CI: 0.61-1.14). Furthermore, significant reductions were observed in myocardial infarction (RR: 0.59; 95% CI: 0.44-0.78) and stent thrombosis (RR: 0.55; 95% CI: 0.3-0.996), with stroke also seeing a decrease (RR: 0.56; 95% CI: 0.35-0.9).
Conclusion: Genotype-guided P2Y12 inhibitor therapy significantly improves outcomes for post-PCI patients, reducing mortality, MACE, myocardial infarction, and stent thrombosis without increasing bleeding risk. These findings support the integration of genetic testing into clinical decision-making for DAPT optimization.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10557-025-07747-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of clopidogrel and ticagrelor in acute coronary syndrome patients with loss-of-function alleles after percutaneous coronary intervention: based on the Global Registry of Acute Coronary Events score.
Res Pract Thromb Haemost
August 2025
Department of Cardiology, State Key Laboratory of Frigid Zone Cardiovascular Disease, General Hospital of Northern Theater Command, Shenyang, China.
Background: The selection of P2Y12 inhibitors for acute coronary syndrome patients after percutaneous coronary intervention (PCI) remains controversial among East Asian patients.
Objectives: This study aimed to identify the optimal P2Y12 inhibitor selection for the East Asian population carrying loss-of-function (LOF) alleles based on the Global Registry of Acute Coronary Events (GRACE) score.
Methods: Between March 2016 and March 2019, a cohort of 8683 patients diagnosed with acute coronary syndrome who survived PCI were enrolled in this study.
Beyond the trials: What real-world data reveal about P2Y₁₂ inhibitors in ACS.
Kardiol Pol
September 2025
Cardiology Department, Dr Balmis General University Hospital, Alicante Institute for Health and Biomedical Research (ISABIAL), Alicante, Spain.
Comparison of Fixed-Dose Clopidogrel/Asetylsalicylic Acid Combination and Standard Loading Strategy During Percutaneous Coronary Intervention in Chronic Coronary Syndrome.
Catheter Cardiovasc Interv
September 2025
Department of Cardiology, Bakırçay University, Izmir, Turkey.
Background: Dual antiplatelet therapy (DAPT), comprising acetylsalicylic acid and a P2Y12 receptor inhibitor such as clopidogrel, is the cornerstone of management in patients undergoing percutaneous coronary intervention (PCI). While conventional loading doses of acetylsalicylic acid and clopidogrel are well established, there is limited evidence supporting the use of fixed-dose combinations (FDCs) for loading therapy in patients with chronic coronary syndrome (CCS).
Aims: This study aims to evaluate the efficacy and safety of an FDC of clopidogrel and acetylsalicylic acid (75/75 mg, four tablets) compared to the standard loading regimen in patients with CCS undergoing elective PCI.
Early Discontinuation of Aspirin after PCI in Low-Risk Acute Myocardial Infarction.
N Engl J Med
August 2025
Cardiology Department, Nimes University Hospital, Montpellier University, ACTION Study Group, Nimes, France.
Background: An appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention for acute myocardial infarction that has been treated with guideline-recommended complete revascularization and a contemporary drug-eluting stent remains unclear.
Methods: We conducted a multicenter, open-label, randomized trial at 40 European sites. Adults with acute myocardial infarction who had undergone successful complete revascularization within 7 days after the infarction and had subsequently completed 1 month of dual antiplatelet therapy with no ischemic or major bleeding events were randomly assigned to transition to a P2Y12 inhibitor as monotherapy or to continue dual antiplatelet therapy for an additional 11 months.
Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes.
N Engl J Med
August 2025
Hospital Israelita Albert Einstein, São Paulo.
Background: Whether potent P2Y12 inhibitor monotherapy without aspirin initiated shortly after successful percutaneous coronary intervention (PCI) is effective and safe for patients with acute coronary syndromes is unclear.
Methods: We conducted a multicenter, open-label, randomized trial in Brazil involving patients with acute coronary syndromes who had undergone successful PCI. Patients were assigned in a 1:1 ratio within the first 4 days of hospitalization to stop treatment with aspirin and receive potent P2Y12 inhibitor monotherapy (ticagrelor or prasugrel) or to receive dual antiplatelet therapy (aspirin and a potent P2Y12 inhibitor) for 12 months.